A Phase 2 RCT Study of CX-8998 for Essential Tremor

Investigator: Olga Waln, MD

Study Coordinator: Titilayo Olubajo

Status: Enrolling

ClinicalTrials.gov Number: NCT03101241

Phone: 713.441.3780

IRB Number: Pro00017175

Description

This is a multi-center, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of subjects on Primidone at baseline who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening results from all patients meeting the eligibility requirements will be further assessed by the sponsor medical personnel for final approval of suitability for inclusion in the study. Randomized subjects will enter a 4 week double-blind dose-titration treatment period, followed by a 1 week safety follow-up period following the last dose of study medication, and a scheduled follow-up safety telephone call one week later.
More to Explore